Mechanistic Analysis of AβO-Induced Neurotoxicity and Tau Pathology in an Inducible MC65 Cell Model

Session Number

1

Advisor(s)

Raghad Nowar, Kirsten Viola, William Klein, Northwestern University, Klein Lab

Location

A123

Discipline

Medical and Health Sciences

Start Date

15-4-2026 10:15 AM

End Date

15-4-2026 11:00 AM

Abstract

Alzheimer’s disease is characterized by the buildup of amyloid-β oligomers (AβOs), tau pathology, and eventual neuronal loss. Yet, the mechanisms that link these processes remain incompletely understood. This project looks into whether induction of AβO in MC65 cells drives neurotoxicity through increased tau phosphorylation and other associated cellular stress pathways. The MC65 model allows for intracellular AβO accumulation through withdrawal of tetracycline (-Tet), while tetracycline presence (+Tet) suppresses Aβ production and serves to be a healthy baseline. To look into downstream tau pathology, we use the PHF1 antibody towards immunofluorescence staining to detect phosphorylated tau (p-Tau) under induced and uninduced conditions. Increased PHF1 fluorescence intensity in -Tet cells compared toTet controls indicated elevated tau phosphorylation following the buildup of AβOs. These observations support the link between amyloid toxicity and tau pathology in this model system. Comparably, cell viability and oxidative stress was evaluated to assess the impact of induced toxicity from AβOs. We build a computational model, specifically a pipeline that measures p-Tau intensity per cell, quantifies the proportion of p-Tau positive cells, and relates these measures to cellular health. In short, this work clarifies the relationship of amyloid toxicity and neurodegeneration along with a framework for quantifying cellular relationships.

Share

COinS
 
Apr 15th, 10:15 AM Apr 15th, 11:00 AM

Mechanistic Analysis of AβO-Induced Neurotoxicity and Tau Pathology in an Inducible MC65 Cell Model

A123

Alzheimer’s disease is characterized by the buildup of amyloid-β oligomers (AβOs), tau pathology, and eventual neuronal loss. Yet, the mechanisms that link these processes remain incompletely understood. This project looks into whether induction of AβO in MC65 cells drives neurotoxicity through increased tau phosphorylation and other associated cellular stress pathways. The MC65 model allows for intracellular AβO accumulation through withdrawal of tetracycline (-Tet), while tetracycline presence (+Tet) suppresses Aβ production and serves to be a healthy baseline. To look into downstream tau pathology, we use the PHF1 antibody towards immunofluorescence staining to detect phosphorylated tau (p-Tau) under induced and uninduced conditions. Increased PHF1 fluorescence intensity in -Tet cells compared toTet controls indicated elevated tau phosphorylation following the buildup of AβOs. These observations support the link between amyloid toxicity and tau pathology in this model system. Comparably, cell viability and oxidative stress was evaluated to assess the impact of induced toxicity from AβOs. We build a computational model, specifically a pipeline that measures p-Tau intensity per cell, quantifies the proportion of p-Tau positive cells, and relates these measures to cellular health. In short, this work clarifies the relationship of amyloid toxicity and neurodegeneration along with a framework for quantifying cellular relationships.